Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Celgene Sets Sights On Becoming Inflammation and Immunology Power Player

Executive Summary

Celgene will buy Receptos for $7.2 billion, gaining the late-stage drug ozanimod in development for multiple sclerosis and ulcerative colitis. With the addition of ozanimod, the company will have three late-stage drugs in its inflammation and immunology portfolio.


Related Content

Neuroscience Reaches A New Inflection Point, Big Biotechs Say
Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Celgene Diversifying Beyond Myeloma Backbone Revlimid
Deal Watch: Immunocore Raises Biggest EU Financing, $320M, For TCR Biologics Program
Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity
Celgene Makes A Play For Inflammation & Immunology Stake With Apremilast


Related Companies

Related Deals